CRISPR company Intellia names CFO
This article was originally published in Scrip
Intellia Therapeutics, founded to develop curative medicines utilizing CRISPR/Cas9 technology for gene editing and repair, has appointed Sapna Srivastava chief financial and strategy officer. Dr Srivastava has experience in the biopharmaceutical industry and on Wall Street. Prior to joining Intellia she was senior analyst and team leader of the biotechnology group at Goldman Sachs.
You may also be interested in...
A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.
Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.
Health care funding in the first half of 2020 reached $10.4bn, according to a mid-year report from Silicon Valley Bank, nearly matching 2019’s full-year record. As well as the COVID-19 pandemic though, other global events, such as the US election, could become distractions in the second half of the year.